title: Vemurafenib-induced radiation recall dermatitis: case report and review of the literature.
abstract: The cutaneous effects of BRAF (serine/threonine protein kinase B-raf) inhibitors such as vemurafenib remain poorly defined. Rash, squamous cell carcinoma, keratoacanthoma and photosensitivity are the most common grade 2 or 3 adverse events observed in clinical trials. We here report the case of a patient with a BRAF V600E mutated metastatic melanoma who developed severe radiation recall dermatitis 6 weeks after completing radiotherapy. Vemurafenib treatment had been initiated 1 week before the development of dermatitis because of rapidly progressing disease. Upon topical treatment of the affected skin areas, clinical symptoms regressed over a period of 2 months, although vemurafenib was continuously administered. As our case goes in line with other reports, we believe that physicians should be aware of this additional cutaneous side effect of vemurafenib and that continuation of the treatment is safe when close clinical control and interdisciplinary management can be provided.
authors.affiliation: Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.
authors.forename: Katrin
authors.initials: K
authors.lastname: Conen
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Mosna-Firlejczyk
authors.forename: Christoph
authors.initials: C
authors.lastname: Rochlitz
authors.forename: Andreas
authors.initials: A
authors.lastname: Wicki
authors.forename: Peter
authors.initials: P
authors.lastname: Itin
authors.forename: Andreas W
authors.initials: AW
authors.lastname: Arnold
authors.forename: Markus
authors.initials: M
authors.lastname: Gross
authors.forename: Frank
authors.initials: F
authors.lastname: Zimmermann
authors.forename: Alfred
authors.initials: A
authors.lastname: Zippelius
mesh_terms: D000368:Aged; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000532:radiotherapy; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D011855:Radiodermatitis / Q000209:etiology*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D013449:Sulfonamides / Q000009:adverse effects*; D000077484:Vemurafenib
chemical_list: D007211:Indoles; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf